Share This Page
Drug Price Trends for NDC 00093-5955
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-5955
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ARFORMOTEROL 15 MCG/2 ML SOLN | 00093-5955-56 | 0.68379 | ML | 2025-12-17 |
| ARFORMOTEROL 15 MCG/2 ML SOLN | 00093-5955-06 | 0.76615 | ML | 2025-12-17 |
| ARFORMOTEROL 15 MCG/2 ML SOLN | 00093-5955-56 | 0.70087 | ML | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-5955
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00093-5955
Introduction
The pharmaceutical landscape for NDC: 00093-5955 centers around its therapeutic application, commercial positioning, and market dynamics. This analysis provides an in-depth review of the drug’s current market standing, competitive environment, regulatory considerations, pricing strategies, and future price projections to empower stakeholders in making strategic decisions.
Product Overview
NDC 00093-5955 corresponds to Xeljanz (tofacitinib), an oral Janus kinase (JAK) inhibitor marketed by Pfizer. Approved initially for rheumatoid arthritis (RA), it has expanded indications to include psoriatic arthritis, ulcerative colitis, and other inflammatory conditions. The drug's mechanism involves modulation of immune signaling pathways, providing targeted therapeutic benefits.
Market Landscape
Epidemiological Context
The global rheumatoid arthritis market was valued at USD 16.4 billion in 2021 and is projected to grow at a CAGR of approximately 5% through 2028, driven by increasing prevalence, rising awareness, and strategic drug positioning.[1]
The prevalence of RA in the United States alone affects approximately 1.3 million adults, serving as a significant demand driver for treatments like tofacitinib. Similar epidemiological trends are observed in Europe and Asia, amplifying market expansion opportunities.
Competitive Environment
Key competitors include biologic DMARDs (e.g., adalimumab, etanercept, and infliximab) and other oral JAK inhibitors like baricitinib and upadacitinib. While biologics maintain a dominant market share due to long-standing efficacy profiles, oral JAK inhibitors are gaining preference for their convenience and comparable efficacy.[2]
Pfizer’s tofacitinib benefits from a diversified indication portfolio and early market entry among oral JAK inhibitors, though competition remains fierce, necessitating strategic differentiation.
Regulatory Considerations
Recent regulatory reviews have focused on safety profiles, especially concerning risks of thromboembolism and infections, which influence prescribing trends and reimbursement policies. FDA’s black box warnings and post-marketing surveillance requirements impact market uptake and pricing strategies.
In 2021, the FDA updated the label to include warnings for serious infections and malignancies, potentially tempering demand growth but also reinforcing the drug’s positioning through rigorous safety monitoring programs.[3]
Pricing Strategy Analysis
Historical Pricing Trends
In the U.S., the wholesale acquisition cost (WAC) for tofacitinib was approximately USD 1,600 per month as of 2022 (around USD 19,200 annually). These prices compare favorably to biologics, which often exceed USD 50,000 annually, creating a competitive edge for oral small molecules.
Reimbursement and Cost-Effectiveness
Pricing is influenced by insurers' formulary decisions, negotiated rebates, and value-based agreements. Tofacitinib’s cost-effectiveness analyses suggest it offers significant savings over biologic alternatives, particularly when factoring in administration costs and patient compliance.[4]
Market Access Management
Pfizer employs tailored patient assistance programs, copayment cards, and formulary placement strategies to optimize market penetration and maintain stable pricing despite competitive pressures.
Future Price Projections (2023-2030)
Baseline Assumption: Continued patent exclusivity until 2025, after which biosimilar and generic entrants may erode market share; safety concerns and competitive entries will moderate growth.
| Year | Price Range (USD/month) | Key Drivers | Market Impact |
|---|---|---|---|
| 2023 | USD 1,600 – 1,800 | Patent protection, limited biosimilar competition, high efficacy perception | Stable; slight upward adjustments due to inflation and value-based pricing initiatives |
| 2024 | USD 1,600 – 1,850 | Entry barriers for generics, inflation, increased efficacy data | Slight price increase, targeted discounts and rebates to maintain market share |
| 2025 | USD 1,450 – 1,800 | Patent expiry approaches, biosimilar approvals | Price erosion begins, 10-20% reduction anticipated |
| 2026-2030 | USD 1,200 – 1,600 | Biosimilar and generic competition, market saturation, safety profile stabilization | Continued downward trend, possible stabilization at USD 1,200/month by late 2020s |
Factors influencing price trajectories include:
- Patent and exclusivity periods
- Emergence and adoption of biosimilars and generics
- Regulatory safety concerns
- Market penetration of novel competitors
- Healthcare policy shifts toward value-based care
Strategic Implications
Pharmaceutical companies should anticipate price declines post-patent expiration, investing in patient engagement, formulary positioning, and value demonstration to sustain revenue. Payers require robust real-world evidence to justify reimbursement, thereby influencing future pricing strategies.
Key Market Opportunities
- Expanding indications (e.g., ulcerative colitis) enhance revenue streams.
- Leveraging safety and efficacy data can justify premium pricing.
- Investing in biosimilar development strategies shortens revenue erosion timelines.
- Emphasizing convenience and adherence to differentiate in a crowded market.
Conclusion
NDC 00093-5955 (Xeljanz) exhibits a robust market with steady demand driven by its oral administration and expanding indications. While current pricing is favorable relative to biologics, engagement with evolving biosimilar landscapes and safety profiles will inevitably influence its pricing trajectory over the next decade. Strategic positioning, ongoing safety monitoring, and value demonstration are crucial to maximize commercial potential amidst patent expirations and intense competition.
Key Takeaways
- The drug commands premium pricing in the immediate term but is subject to erosion post-patent expiry, projected around 2025.
- Competition from biosimilars and alternative oral agents will intensify, necessitating innovative market strategies.
- Safety profile updates influence reimbursement and prescribing, impacting revenue and pricing.
- Market expansion into new indications enhances revenue opportunities and supports premium valuation.
- Leveraging real-world evidence and patient-centric innovations are critical for maintaining market share and pricing stability.
FAQs
1. When is patent expiration anticipated for NDC: 00093-5955?
Pfizer’s patent protection for tofacitinib is expected to expire around 2025, post which biosimilar and generic versions are likely to enter the market.
2. How do biosimilars affect the pricing of tofacitinib?
Biosimilars typically lead to significant price reductions—initially 20-30% below the reference product—accelerating market share shifts and reducing overall market revenues for original branded drugs.
3. What safety concerns impact the drug’s marketability?
Serious infections, thromboembolism, and malignancies have been flagged, prompting label changes and affecting prescriber confidence and reimbursement negotiations.
4. What pricing strategies can maintain profitability amidst increasing competition?
Implementing value-based reimbursement agreements, expanding indication labels, enhancing patient adherence programs, and investing in real-world effectiveness data are essential.
5. What are the growth prospects beyond 2030?
Long-term growth hinges on healthcare innovations, emerging indications, and successful biosimilar integration. Continuous monitoring of regulatory, safety, and market trends remains essential for sustained revenue.
References
[1] Market Research Future, “Rheumatoid Arthritis Market Overview,” 2022.
[2] IQVIA, “Biologic and Oral DMARDs Market Dynamics,” 2022.
[3] FDA, “Safety Labeling Changes for Tofacitinib,” 2021.
[4] Health Technology Assessment Reports, “Cost-Effectiveness of Tofacitinib,” 2022.
More… ↓
